Journal
European Journal of Cancer
Publication Date
3-26-2025
Volume
219
First Page
115306
Document Type
Open Access Publication
DOI
10.1016/j.ejca.2025.115306
Rights and Permissions
Vergote I, Copeland LJ, Van Gorp T, Laenen A, Scambia G, Thaker PH, Cibula D, Colombo N, Lea J, Gonzalez-Martin A, Korach J, Sehouli J, Monk BJ, Heinzelmann-Schwarz V, Berger R, Buscema J, Lau S, Mądry R, Denys H, Pepin JT, Salutari V, Bagaméri A, Ardizzoia A, Henry S, Cecere SC, Hruda M, Iglesias DA, Manso L, Shai A, O'Malley DM; ENGOT-ov50/GOG-3029/INNOVATE-3 Study Investigators. Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study. Eur J Cancer. 2025 Mar 26;219:115306. doi: 10.1016/j.ejca.2025.115306. © 2025 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Recommended Citation
Vergote, Ignace; Thaker, Premal H; and et al., "Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study." European Journal of Cancer. 219, 115306 (2025).
https://digitalcommons.wustl.edu/oa_4/5507
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
